SEC Form 4 · accession 0001584759-26-000015
Oric Pharmaceuticals, Inc. · ORIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A. Heyman
Director
Period of report
Jul 24, 2026
Accepted (ET)
Jul 28, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001796280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 24, 2026 | M | 3,500 | $1.60 | A | 45,300 | D | |
| Common Stock | Jul 24, 2026 | S | 7,000 | $12.02 | D | 38,300 | D | |
| Common StockF2 | Jul 24, 2026 | S | 6,100 | $12.02 | D | 206,672 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.60 | Jul 24, 2026 | M | 3,500 | D | — | Feb 28, 2028 | Common Stock | 3,500 | 30,200 | D |
Explanation of responses
- F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
- F2The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
- F3The shares subject to the option are fully vested and immediately exercisable.